Equity Profile

FMS

Fresenius Medical Care AG

Health CareHealth Care Services$12.6B

May5Tue

Pre-Earnings Brief

UpcomingQ1-2026After Close9:00 AM EDT

Company Snapshot

Fresenius Medical Care AG (FMS) is a leading provider of products and services for individuals with renal diseases. Operating in the health care sector, the company focuses on dialysis services and related products, making it vital for patients with kidney issues....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing costs and generating profit.

$0.50

Revenue

Revenue reflects the company's sales performance and overall demand for its dialysis services and products.

$4.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

FMS Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-6.74%

Avg Stock Reaction

-1.23%

Last Quarter Recap

In Q1 2023, Fresenius Medical Care reported an EPS of $0.17, slightly missing the estimate of $0.18. The stock reacted with a minor decline of 0.09% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Fresenius Medical Care to report an EPS of $0.50 and revenue of $4.6 billion this quarter. The market will closely watch these figures to gauge the company's recovery and growth potential.

Bull Case

If Fresenius exceeds expectations, it could indicate strong demand for its services and improved operational efficiency, potentially leading to a positive stock reaction.

Bear Case

Conversely, if the company misses its targets, it may raise concerns about its ability to navigate challenges in the health care sector, leading to a negative market response.

Key Metrics to Watch

EPS

$0.50

Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing costs and generating profit.

Revenue

$4.6B

Revenue reflects the company's sales performance and overall demand for its dialysis services and products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $0.50?

A higher EPS would signal better-than-expected profitability and could boost investor confidence.

What are the revenue figures compared to the expected $4.6 billion?

Revenue performance is crucial for understanding demand for Fresenius's services and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for revenue growth driven by increasing demand for dialysis services, especially in emerging markets.

Supporting Evidence

The options market is pricing a 4.4% move, suggesting higher volatility expectations than historical averages.

Fresenius has a history of surprising on the upside, with a 31% beat in Q2 2020, indicating potential for positive surprises.

The aging population and rising chronic kidney disease rates could drive demand beyond current estimates.

Key Risk

If revenue comes in above $4.6 billion, it could significantly alter the market's perception of Fresenius's growth trajectory.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is evaluating Fresenius's ability to recover from previous earnings misses and its capacity to grow in a competitive health care landscape.

Bull Confirmed If

An EPS above $0.50 and revenue exceeding $4.6 billion would confirm a positive outlook.

Bear Confirmed If

An EPS below $0.47 or revenue under $4.5 billion would indicate significant challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±4.4%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a move of about 4.4% in either direction, indicating uncertainty around the earnings report.

Options are pricing ±4.4% while FMS has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

30d HV

22.1%

Calls (300)P/C Ratio: 1.00Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders trimming

Institutional

8.64%

of float

Insider

0.00%

of float

Holders

255

institutions

Top Holders· as of Dec 2025

Pzena Investment Management LLC
14,752,836 sh · $335.9M
2.64%
-0.4%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Fresenius beats expectations, history suggests a potential stock increase of around 2.69%, confirming a recovery narrative.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting ongoing uncertainty in the health care sector.

Miss

If the company misses its targets, the average reaction has been a decline of about 1.23%, indicating market disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on demand trends for dialysis services.
2Insights on cost management and operational efficiency improvements.
3Comments on competitive pressures in the health care sector.
4Future guidance on revenue and EPS expectations.
5Any strategic initiatives targeting emerging markets.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing costs and generating profit.

$0.50

Revenue

Revenue reflects the company's sales performance and overall demand for its dialysis services and products.

$4.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

FMS Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-6.74%

Avg Stock Reaction

-1.23%

Last Quarter Recap

In Q1 2023, Fresenius Medical Care reported an EPS of $0.17, slightly missing the estimate of $0.18. The stock reacted with a minor decline of 0.09% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Fresenius exceeds expectations, it could indicate strong demand for its services and improved operational efficiency, potentially leading to a positive stock reaction.

Bear Case

Conversely, if the company misses its targets, it may raise concerns about its ability to navigate challenges in the health care sector, leading to a negative market response.

Key Metrics to Watch

EPS

$0.50

Earnings per share (EPS) is a key indicator of profitability and will show how well the company is managing costs and generating profit.

Revenue

$4.6B

Revenue reflects the company's sales performance and overall demand for its dialysis services and products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $0.50?

A higher EPS would signal better-than-expected profitability and could boost investor confidence.

What are the revenue figures compared to the expected $4.6 billion?

Revenue performance is crucial for understanding demand for Fresenius's services and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for revenue growth driven by increasing demand for dialysis services, especially in emerging markets.

Supporting Evidence

The options market is pricing a 4.4% move, suggesting higher volatility expectations than historical averages.

Fresenius has a history of surprising on the upside, with a 31% beat in Q2 2020, indicating potential for positive surprises.

The aging population and rising chronic kidney disease rates could drive demand beyond current estimates.

Key Risk

If revenue comes in above $4.6 billion, it could significantly alter the market's perception of Fresenius's growth trajectory.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is evaluating Fresenius's ability to recover from previous earnings misses and its capacity to grow in a competitive health care landscape.

Bull Confirmed If

An EPS above $0.50 and revenue exceeding $4.6 billion would confirm a positive outlook.

Bear Confirmed If

An EPS below $0.47 or revenue under $4.5 billion would indicate significant challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±4.4%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a move of about 4.4% in either direction, indicating uncertainty around the earnings report.

Options are pricing ±4.4% while FMS has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

30d HV

22.1%

Calls (300)P/C Ratio: 1.00Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders trimming

Institutional

8.64%

of float

Insider

0.00%

of float

Holders

255

institutions

Top Holders· as of Dec 2025

Pzena Investment Management LLC
14,752,836 sh · $335.9M
2.64%
-0.4%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Fresenius beats expectations, history suggests a potential stock increase of around 2.69%, confirming a recovery narrative.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting ongoing uncertainty in the health care sector.

Miss

If the company misses its targets, the average reaction has been a decline of about 1.23%, indicating market disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on demand trends for dialysis services.
2Insights on cost management and operational efficiency improvements.
3Comments on competitive pressures in the health care sector.
4Future guidance on revenue and EPS expectations.
5Any strategic initiatives targeting emerging markets.